Solid Tumors
Conditions
Interventions
Advanced Non-Small Cell Lung Cancer (First-Line, Second-Line, =Third-Line Therapy):None
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (First-Line, Second-Line, =Third-Line Therapy):None
Advanced Colorectal Cancer (First-Line, Second-Line, =Third-Line Therapy):None
Other HER-2 Altered or Low-Expression Advanced Solid Tumors:None
Sponsors
The First Affiliated Hospital of Jinzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Signing of informed consent and voluntary participation in the study. 2. Histologically or cytologically confirmed advanced solid tumor. 3. Age>=18 years. 4. Documented HER-2 alteration, including HER-2 mutation, HER-2 amplification, HER-2 positivity (IHC 3+ or IHC 2+/ISH+), or HER-2 low expression (IHC 2+/ISH- or IHC 1+). 5. The investigator considers the patient suitable for treatment with Trastuzumab Deruxtecan (SHR-1811) as monotherapy or in combination therapy.
Exclusion criteria
Exclusion criteria: 1. Patients who are concurrently receiving other therapeutic agents of the same class. 2. Patients currently participating in other interventional studies. 3. Patients who are pregnant or lactating (confirmed by testing). 4. Any other condition where, in the opinion of the investigator, the patient is not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events >= Grade 3; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression Free Survival, PFS;Overall survival;Intracranial Objective Response Rate, iORR;Intracranial Progression Free Survival, iPFS; | — |
Countries
China
Contacts
Public ContactXiaomei Liu
The First Affiliated Hospital of Jinzhou Medical University
Outcome results
None listed